Isofol announces that an abstract about Modufolin® in osteosarcoma treatment will be presented at ESMO 2017
Isofol Medical AB (publ) announces that an abstract about Modufolin® has been accepted to be presented at ESMO 2017, taking […]
News
Scrip Intelligence, a leading source of news and strategic analysis for the global pharmaceutical industry, publish article about Isofol Medical
John Davis, journalist and editor for more than 30 years, of Scrip Intelligence recently interviewed Anders Rabbe, CEO of Isofol
Isofol has enrolled and dosed its first group of patients in the IND-study ISO-FF-001
Isofol Medical AB (publ) announced today that the first six patients were enrolled and dosed in the ISO-FF-001 study. The
New scientific findings strengthen rationale and motivation for Isofol Medical to conduct the pivotal ISO-CC-007 study
Isofol Medical AB (publ) announced today that academic researchers collaborating with Isofol have presented results last week at ESMO-GI which
Isofol has initiated five additional study sites in the ISO-CC-005 study in which Modufolin® is evaluated in colorectal cancer
Isofol Medical AB (publ) announced today that the last one of five additional study sites was initiated in Greece and
Isofol Announces Publication of an Abstract for the 2017 ASCO Annual Meeting
Isofol Medical AB (publ) announces publication of an abstract regarding failure rate of standard rescue after high-dose methotrexate in osteosarcoma
Pareto Securities has notified Isofol Medical AB that stabilisation measures regarding the Company’s shares have been taken
In connection with the offering to acquire newly issued shares in Isofol and the listing on Nasdaq First North Premier
Isofol accepted for presentation of abstract at the 2017 ASCO annual meeting
Isofol Medical AB (publ) announces that an abstract has been accepted to be presented at the American Society of Clinical
Pareto Securities has notified Isofol Medical AB (publ) that stabilisation measures regarding the Company’s shares have been taken
In connection with the offering to acquire newly issued shares in Isofol and the listing on Nasdaq First North Premier
Pareto Securities has notified Isofol Medical AB that stabilisation measures regarding the Company’s shares have been taken
For a complete press release follow the link http://isofol.se/en/ipo/ For additional information, please contact: Anders Rabbe, Managing Director, Isofol Mob: +46 70